Floatz logo

Micardis®

Hypertriglyceridemia

Ludwig-Maximilians - University of MunichPhase 3Dormant
B
62/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
47/ 100
Competitive Position
95/ 100

Competitive context

5 Active assets in the Hypertriglyceridemia cohort.

Asset / SponsorPhaseRating
Fenofibrate
Abbott
Phase 4BB
Amprenavir
Felizarta, Franco, M.D.
Phase 4BB
Saffron
Birjand University of Medical Sciences
Phase 4BB
Lipitor
The University of Western Australia
Phase 4BB
RITONAVIR
Felizarta, Franco, M.D.
Phase 4BB

View all 27 →

Same molecule, other indications

Micardis® is also rated in:

hypertensive disorderDormant
BB
Indicative ·
71 / 100
View asset →
abdominal obesity-metabolic syndromeDormant
BB
Indicative ·
70 / 100
View asset →
schizoaffective disorderDormant
BB
Indicative ·
68 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →